The endothelial isoform of nitric-oxide synthase (eNOS), a key determinant of vascular homeostasis, is a calcium/calmodulindependent phosphoprotein regulated by diverse cell surface receptors. Vascular endothelial growth factor (VEGF) and sphingosine 1-phosphate (S1P) stimulate eNOS activity through Akt/phosphoinositide 3-kinase and calcium-dependent pathways. AMP-activated protein kinase (AMPK) also activates eNOS in endothelial cells; however, the molecular mechanisms linking agonist-mediated AMPK regulation with eNOS activation remain incompletely understood. We studied the role of AMPK in VEGF-and S1P-mediated eNOS activation and found that both agonists led to a striking increase in AMPK phosphorylation in pathways involving the calcium/calmodulin-dependent protein kinase kinase . Treatment with tyrosine kinase inhibitors or the phosphoinositide 3-kinase inhibitor wortmannin demonstrated differential effects of VEGF versus S1P. Small interfering RNA (siRNA)-mediated knockdown of AMPK␣1 or Akt1 impaired the stimulatory effects of both VEGF and S1P on eNOS activation. AMPK␣1 knockdown impaired agonist-mediated Akt phosphorylation, whereas Akt1 knockdown did not affect AMPK activation, thus suggesting that AMPK lies upstream of Akt in the pathway leading from receptor activation to eNOS stimulation. Importantly, we found that siRNA-mediated knockdown of AMPK␣1 abrogates agonist-mediated activation of the small GTPase Rac1. Conversely, siRNA-mediated knockdown of Rac1 decreased the agonist-mediated phosphorylation of AMPK substrates without affecting that of AMPK, implicating Rac1 as a molecular link between AMPK and Akt in agonist-mediated eNOS activation. Finally, siRNA-mediated knockdown of caveolin-1 significantly enhanced AMPK phosphorylation, suggesting that AMPK is negatively regulated by caveolin-1. Taken together, these results suggest that VEGF and S1P differentially regulate AMPK and establish a central role for an agonist-modulated AMPK 3 Rac1 3 Akt axis in the control of eNOS in endothelial cells.
cGMP is involved in numerous vascular signaling pathways, and abnormalities in these pathways have been implicated in the pathophysiology of hypertension, atherosclerosis, and diabetes (1, 2). In endothelial cells, cGMP is synthesized by two distinct guanylate cyclase (GC) 5 isoforms, the nitric oxide (NO)-activated soluble GC (sGC) and the atrial natriuretic peptide (ANP)-activated particulate GC (GC-A) (2-4). NO, produced by endothelial NO synthase (eNOS), plays a crucial role in a variety of vascular responses such as blood pressure control, platelet aggregation, and vascular smooth muscle cell proliferation (5). Activation of eNOS is strongly influenced by a diverse collection of cell surface receptors, including vascular endothelial growth factor (VEGF) receptor (KDR) and sphingosine 1-phosphate (S1P) receptor S1P 1 (Edg-1) (6, 7). ANP is released primarily by cardiac atria in response to atrial stretch; this peptide binds with high affinity to the membrane receptor guanylate cyclase GC-A located in renal cells and in the vasculature (8, 9). Activated GC-A promotes diuresis and inhibits the renin-angiotensin-aldosterone system, thereby controlling salt and water retention and blood pressure (10). Recent studies have revealed ANP to be an endogenous vasoprotective substance as well as a potent pharmacological agent in the treatment of cardiovascular diseases (10 -12). GC-A is abundantly expressed in the vascular endothelium, and binding of ANP to GC-A significantly increases intracellular cGMP levels (13-15).The principal effectors of cGMP in the cardiovascular system include cGMP-gated monovalent cation channels, phosphodiesterases, and cGMP-dependent protein kinases (PKGs) (16,17). Two mammalian PKG genes have been identified, encoding PKG I and PKG II. PKG I is the prevalent PKG isoform expressed in the cardiovascular system (17) and will be referred to here as PKG. Although the functions of PKG have been probed both with PKG knock-out mice and with analyses of cellular substrates phosphorylated by PKG, much remains to be understood about the molecular and cellular significance of PKG signaling in endothelial homeostasis. PKG knock-out mice display decreased life span, impaired vascular smooth * This work was supported in part by Grants HL46457, HL48743, GM36259 (to T. M.), HL32854, and HL70819 (to D. E. G.) from the National Institutes of Health. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.